- Home
- ISPR vs EQ Comparison
ISPR vs EQ Comparison
Compare ISPR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPR | EQ |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.7M | 129.0M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ISPR | EQ |
|---|---|---|
| Price | $1.66 | $2.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.50 | ★ $8.00 |
| AVG Volume (30 Days) | 91.4K | ★ 897.7K |
| Earning Date | 05-12-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,494,304.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $0.29 |
| 52 Week High | $3.87 | $3.45 |
Technical Indicators
Market Signals| Indicator | ISPR | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 59.39 |
| Support Level | $1.55 | $1.68 |
| Resistance Level | $1.98 | $3.45 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.01 | 71.81 |
Price Performance
Historical ComparisonAbout ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.